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Prostate cancerAbstract Lawsone (1a) is a known naphthoquinone dye from the Henna plant Lawsonia inermis.
Out of a series of four new ferrocene modified Mannich bases of 1a, the 2-pyridyl derivative 2a was
distinctly more active than its analogs 2b–d in breast, prostate and pancreatic cancer cells. 2a also
exhibited greater antiproliferative effects when compared with the known anticancer active
Mannich bases 1b and 1c in the androgen-receptor negative PC-3 prostate and Pgp-expressing
KB-V1/Vbl cervix carcinoma cell lines. Compound 2a reached sub-micromolar activities in these
aggressive cancer cells and, thus, features a promising drug candidate for the efficient treatment
of hormone- or multidrug-resistant cancer types.
 2016 King Saud University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Naphthoquinones feature a large group of plant secondary
metabolites with a broad range of properties including antiox-
idant, anti-inflammatory, anticancer, and antibacterial activi-
ties [1–4]. Lawsone, i.e., 2-hydroxy-1,4-naphthoquinone, (1a,
Fig. 1) is a constituent of the Henna plant (Lawsonia inermis)which has been used in Ayurveda and Unani medicine for cen-
turies mainly for the treatment of skin diseases [5,6]. A natural
lawsone derivative (arabinosyl ester) was recently isolated
from Amomum subulatum fruits growing in Sikkim, India [7].
Lawsone is a potentially useful starting material for the prepa-
ration of other p-quinones with proven or conceivable bioac-
tivity such as atovaquone or lapachol [6]. The readiness with
which lawsone derivatives undergo redox reactions and chela-
tion of metal ions is likely responsible for at least a few of their
biological activities [8–10]. Mannich bases have raised interest
in the field of drug design and Mannich bases from lawsone
have earlier been investigated as potential antimalarial agents
[11,12]. A series of anticancer active 3-aminomethyl-
naphthoquinones (Mannich bases 1b and 1c) derived from
lawsone 1a together with their N,N-chelate platinum com-
plexes was disclosed (Fig. 1) [13–15].
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Figure 1 Chemical structures of lawsone (1a) and of two
published anticancer active Mannich bases 1b and 1c.
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phenyl surrogates and isosters has been reviewed thoroughly
[16,17]. In addition, enhanced tumor selectivity of the non-
discriminating fungal cytotoxin illudin M by esterification with
ferrocene-1,10-dicarboxylate was observed [18–20]. Concerning
pathological bugs and parasites, ferrocene-modified aminohy-
droxynaphthoquinones derived from lawsone exhibited para-
site growth inhibitory activity against Toxoplasma gondii [21].
For the current study, we further developed the anticancer
active lawsone Mannich base motifs of 1b and 1c by attach-
ment of ferrocene scaffolds. First, we modified the N-alkyl side
chain by a ferrocenylmethyl moiety. Second, we replaced the 2-
pyridyl group by other aryl moieties like 4-pyridyl, 3,4-
difluorophenyl or ferrocenyl groups. The growth inhibitory
activity of the new ferrocene-lawsone conjugates was deter-
mined in various cancer cell types that are difficult to tackle
by approved anticancer drugs.
2. Experimental
2.1. General
Melting points were recorded using a Gallenkamp apparatus
and are uncorrected. IR: Perkin-Elmer Spectrum One FT-IR
spectrophotometer equipped with an ATR sampling unit.
NMR: Bruker Avance 300 spectrometer; chemical shifts are
given in parts per million (d) downfield from Me4Si as internal
standard; coupling constants (J) are given in Hz. MS: Varian
MAT 311A (EI). Microanalyses indicated by the symbols of
the elements were within ±0.2% of the theoretical values for
all new compounds. The starting compounds and pure solvents
were purchased from the usual sources and were used without
further purification. (Ferrocene-1-yl)-methylamine was pre-
pared according to a literature procedure starting from com-
mercially available ferrocene-1-yl carboxaldehyde [22].
2.2. Chemistry
2.2.1. 3-[(Ferrocen-1-ylmethylamino)(2-pyridyl)methyl]-2-
hydroxy-1,4-naphthoquinone (2a)
2-Hydroxy-1,4-naphthoquinone (101 mg, 0.58 mmol) was sus-
pended in EtOH (15 mL), ferrocene-1-ylmethyl amine (150 mg,0.7 mmol) was added and the resulting solution was stirred at
room temperature for 5 min. Pyridine-2-carboxaldehyde
(73 lL, 0.76 mmol) was added and the reaction mixture was
stirred at room temperature for 5 h. The formed precipitate
was collected, washed with EtOH and dried in vacuum. Yield:
157 mg (0.33 mmol, 57%); amber solid of mp 175–177 C;
mmax (ATR)/cm
1 3083, 3009, 2948, 2634, 1674, 1609, 1587,
1555, 1517, 1472, 1434, 1397, 1377, 1358, 1334, 1274, 1257,
1224, 1209, 1172, 1150, 1107, 1078, 1042, 1026, 994, 966,
937, 914, 901, 874, 832, 819, 797, 774, 742, 723, 696, 665; 1H
NMR (300 MHz, CDCl3) d 3.92 (1 H, d, J= 13.1 Hz), 4.1–
4.2 (3 H, m), 4.2–4.3 (5 H, m), 4.3–4.4 (1 H, m), 4.4–4.5 (1
H, m), 5.83 (1 H, s), 7.1–7.2 (1 H, m), 7.3–7.4 (2 H, m), 7.5–
7.6 (2 H, m), 7.84 (1 H, dd, J= 7.7 Hz, 1.0 Hz), 7.93 (1 H,
dd, J= 7.7 Hz, 1.0 Hz), 8.4–8.5 (1 H, m), 9.7–9.9 (1 H, br
s); 13C NMR (75.5 MHz, CDCl3) d 46.0, 58.5, 68.9, 69.1,
69.2, 69.4, 69.6, 110.5, 122.2, 123.0, 125.6, 126.3, 131.1,
131.6, 133.6, 134.3, 137.7, 147.5, 155.5, 171.3, 181.4, 184.5;
m/z (%) 478 (3) [M+], 460 (9), 411 (26), 304 (100), 265 (26),
239 (63), 215 (72), 199 (82), 174 (45), 121 (44), 105 (30), 56
(22). Anal C27H22FeN2O3 calcd. C, 67.8, H, 4.64, N, 5.86.
Found C, 67.5, H, 4.56, N, 5.77.
2.2.2. 3-[(Ferrocen-1-ylmethylamino)(4-pyridyl)methyl]-2-
hydroxy-1,4-naphthoquinone (2b)
2-Hydroxy-1,4-naphthoquinone (61 mg, 0.35 mmol) was sus-
pended in EtOH (15 mL), ferrocene-1-ylmethyl amine
(90 mg, 0.42 mmol) was added and the resulting solution was
stirred at room temperature for 5 min. Pyridine-4-
carboxaldehyde (43 lL, 0.43 mmol) was added and the reac-
tion mixture was stirred at room temperature for 5 h. The
formed precipitate was collected, washed with EtOH and dried
in vacuum. Yield: 106 mg (0.22 mmol, 63%); red-brown solid
of mp 175–177 C; mmax (ATR)/cm1 3071, 2952, 2606, 1673,
1589, 1522, 1474, 1419, 1374, 1335, 1270, 1222, 1242, 1159,
1106, 1068, 1024, 993, 969, 937, 872, 818, 810, 731, 694, 663;
1H NMR (300 MHz, DMSO-d6) d 3.9–4.0 (2 H, m), 4.1–4.2
(5 H, m), 4.2–4.4 (4 H, m), 5.47 (1 H, s), 7.4–7.5 (2 H, m),
7.59 (1 H, dd, J= 7.3 Hz), 7.71 (1 H, dd, J= 7.4 Hz), 7.83
(1 H, d, J= 7.3 Hz), 7.92 (1 H, d, J= 7.4 Hz), 8.5–8.6 (1
H, m), 9.6–9.8 (1 H, br s); 13C NMR (75.5 MHz, CDCl3) d
44.8, 55.9, 68.7, 70.2, 70.6, 76.7, 97.1, 109.7, 122.1, 125.1,
125.5, 131.0, 131.6, 133.8, 134.6, 146.7, 149.6, 170.7, 178.3,
184.0; m/z (%) 411 (36), 304 (100), 265 (43), 215 (59), 199
(96), 121 (70), 56 (24). Anal C27H22FeN2O3 calcd. C, 67.8,
H, 4.64, N, 5.86. Found C, 67.7, H, 4.53, N, 5.75.
2.2.3. 3-[(Ferrocen-1-ylmethylamino)(3,4-difluorophenyl)
methyl]-2-hydroxy-1,4-naphthoquinone (2c)
2-Hydroxy-1,4-naphthoquinone (101 mg, 0.58 mmol) was sus-
pended in EtOH (15 mL), ferrocene-1-ylmethyl amine
(150 mg, 0.7 mmol) was added and the resulting solution
was stirred at room temperature for 5 min. 3,4-
Difluorobenzaldehyde (84 lL, 0.76 mmol) was added and
the reaction mixture was stirred at room temperature for
5 h. The formed precipitate was collected, washed with EtOH
and dried in vacuum. Yield: 290 mg (0.57 mmol, 98%); red-
brown solid of mp 197–198 C; mmax (ATR)/cm1 3134,
3089, 2968, 2563, 1682, 1611, 1591, 1579, 1509, 1474, 1429,
1381, 1353, 1347, 1320, 1276, 1227, 1242, 1193, 1153, 1117,
1103, 1041, 1030, 999, 951, 931, 922, 885, 852, 819, 800,
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Scheme 1 Reagents and conditions: (i) (Ferrocene-1-yl)-methy-
lamine, EtOH, r.t., 5 h, 57–98%.
Ferrocene modified lawsone Mannich bases 107786, 767, 737, 702, 693, 653; 1H NMR (300 MHz, DMSO-d6)
d 3.8–3.9 (2 H, m), 4.1–4.2 (5 H, m), 4.2–4.3 (4 H, m), 5.43 (1
H, s), 7.3–7.4 (2 H, m), 7.5–7.6 (2 H, m), 7.71 (1 H, ddd,
J= 7.6 Hz, 1.4 Hz), 7.83 (1 H, dd, J= 7.6 Hz, 1.0 Hz),
7.91 (1 H, dd, J= 7.6 Hz, 1.0 Hz); m/z (%) 411 (2), 339
(8), 270 (100), 242 (19), 215 (92), 137 (37), 121 (24), 104
(28), 76 (26). Anal C28H21F2FeNO3 calcd. C, 65.52, H,
4.12, N, 2.73. Found C, 65.30, H, 4.02, N, 2.66.
2.2.4. 3-[(Heptylamino)(1-ferrocenyl)]-2-hydroxy-1,4-
naphthoquinone (2d)
2-Hydroxy-1,4-naphthoquinone (217 mg, 1.25 mmol) was sus-
pended in EtOH (15 mL), heptylamine (204 lL, 1.37 mmol)
was added and the resulting solution was stirred at room tem-
perature for 5 min. Ferrocene-1-yl carboxaldehyde (321 mg,
1.5 mmol) was added and the reaction mixture was stirred at
room temperature for 5 h. The formed precipitate was col-
lected, washed with EtOH and dried in vacuum. Yield:
150 mg (0.31 mmol, 25%); brown solid of mp > 130 C
(dec.); mmax (ATR)/cm
1 3087, 2927, 2861, 1674, 1594, 1565,
1530, 1468, 1365, 1337, 1277, 1220, 1157, 1105, 1054, 1022,
1000, 963, 915, 895, 822, 759, 738, 664; 1H NMR (300 MHz,
CDCl3) d 0.7–0.8 (3 H, m), 1.0–1.6 (10 H, m), 2.9–3.0 (2 H,
m), 3.8–3.9 (2 H, m), 4.0–4.1 (5 H, m), 4.1–4.2 (2 H, m),
6.82 (1 H, s), 7.4–7.5 (1 H, m), 7.5–7.7 (1 H, m), 7.7–7.8 (1
H, m), 8.1–8.2 (1 H, m); 13C NMR (75.5 MHz, CDCl3) d
13.9, 22.4, 28.7, 31.5, 66.2, 68.6, 69.1, 123.9, 125.4, 126.9,
130.8, 131.9, 133.3, 134.1, 174.1, 183.6, 185.8; Anal C28H31-
FeNO3 calcd. C, 69.28, H, 6.44, N, 2.89. Found C, 69.03, H,
6.19, N, 2.72.
2.3. Biological studies
2.3.1. Cell lines and culture conditions
BxPC-3 pancreas cancer cells (gemcitabine-sensitive) and
MDA-MB-231 breast cancer cells (triple-negative) were pur-
chased from the American Type Culture Collection (ATCC,
Manassas, VA, USA) and maintained in Dulbecco’s modi-
fied Eagle’s medium (DMEM; Invitrogen, Carlsbad, CA,
USA) supplemented with 10% fetal bovine serum (FBS),
100 U/mL of penicillin, and 100 lg/mL of streptomycin.
The prostate cancer cell line PC-3 (androgen receptor/AR-
negative, ATCC, Manassas, VA, USA) was maintained in
RPMI 1640 (Invitrogen, Carlsbad, CA, USA) supplemented
with 10% FBS, 100 U/mL of penicillin, and 100 lg/mL of
streptomycin. Prostate epithelial cells RWPE-1 (ATCC,
Manassas, VA, USA) were cultured in keratinocyte serum
free medium (Life Technologies, Carlsbad, CA, USA) with
0.05 mg/mL bovine pituitary extract and 5 ng/mL human
recombinant epidermal growth factor. The human mela-
noma cell line 518A2 (Department of Radiotherapy and
Radiobiology, University Hospital Vienna), the human
colon adenocarcinoma cell line HT-29 (University Hospital
Erlangen, Germany), and the KB-V1/Vbl cervix cancer cell
line (Institute of Pharmacy, University of Regensburg, Ger-
many) were grown in DMEM or RPMI (HT-29) medium,
supplemented with 10% FBS, 1% Antibiotic–Antimycotic
solution (both from Gibco, Darmstadt, Germany) and
250 lg/mL gentamycin (SERVA, Heidelberg, Germany).
All cells were cultured in a humidified 5% CO2 atmosphere
at 37 C.2.3.2. MTT assay
MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbro
mide] (ABCR) was used to identify viable cells which reduce
it to a violet formazan [23]. Cells (3  103/well) were seeded
and cultured for 24 h on 96-well microplates. Incubation
(5% CO2, 95% humidity, 37 C) of cells following treatment
with the test compounds (dilution series from 5–40 lM in
DMSO) was continued for 72 h. 25 lL of an MTT stock solu-
tion, containing 5 mg/mL in phosphate-buffered saline (PBS),
was added to a final concentration of 0.05% and incubated for
a further 2 h at 37 C. The supernatant was withdrawn and the
formazan was dissolved in DMSO (100 lL). The absorbance at
595 nm was measured on an Ultra Multifunctional Microplate
Reader (Tecan, Durham, NC, USA).
3. Results and discussion
3.1. Chemistry
The new Mannich bases 2a–d were prepared via Mannich reac-
tion of lawsone (1a), aryl carboxaldehyde (2-
pyridylcarboxaldehyde for 2a, 4-pyridylcarboxaldehyde for
2b, and 3,4-difluorobenzaldehyde for 2c) and ferrocene-1-yl
methylamine (Scheme 1). Analogously, compound 2d was
obtained from the reaction of 1a with ferrocene-1-yl carbox-
aldehyde and heptylamine (Scheme 2). The racemic products
precipitated from the reaction mixture as amber or brown
solids after a few hours. 1H NMR spectra revealed the partic-
ularly significant CHNHR signal (5.43–5.83 ppm for 2a–c,
6.82 ppm for 2d) aside the characteristic ferrocene protons
(4.0–4.5 ppm). The 13C NMR spectra of 2a and 2b exhibited
ferrocene signals (68–77 ppm) aside CH2 (44–46 ppm) and
CH signals (55.9–58.5 ppm). In addition, the 13C NMR spec-
trum of 2d showed characteristic carbon signals of the hepty-
lamine residue (13.9–28.7 ppm).
3.2. Biological evaluation
The antiproliferative activity of 1b, 1c, and 2a–d was initially
tested against the triple-negative MDA-MB-231 breast cancer,
the BxPC-3 pancreas cancer, and the PC-3 (AR-) prostate can-
cer cells (Fig. 2). Compound 2a was the most active ferrocene
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Scheme 2 Reagents and conditions: (i) Heptylamine, EtOH,
r.t., 5 h, 25%.
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(2a> 2b> 2d> 2c). Compound 2a also exceeded the activity
of the known lawsone Mannich bases and close analogs 1b and
1c in the PC-3 cells. Prostate cancer cells generally exhibit high
ROS levels leading to aggressive cancer phenotypes [24,25].
The enhanced activity by compound 2a in the PC-3 prostateFigure 2 Growth inhibitory activity (MTT assay) of compounds 1b
BxPC-3 pancreas carcinoma, and androgen receptor-negative PC-3 prcancer cell line may be at least in parts due to activation of
the ferrocene fragment by reactive oxygen species (ROS).
The formation and stabilization of eventually emerging molec-
ular radicals by the different scaffolds used in this study can
influence the anticancer activity of the respective ferrocene
derivatives 2 [26,27]. To confirm the cancer cell-specific activity
of the most active compound 2a, we tested it against the con-
trol prostate epithelial cell line, RWPE-1. We observed that
this compound did not significantly inhibit the proliferation
of these non-malignant cells (Fig. 3).
Further to this, the most active ferrocene derivative 2a was
tested in four aggressive, mutant and/or drug-resistant human
cancer cell lines (518A2 melanoma, vinblastine-resistant KB-
V1/Vbl cervix carcinoma, HCT-116 colon carcinoma, and
HT-29 colon carcinoma) and compared with the activity of
the lawsone Mannich base positive controls 1b and 1c
(Table 1). Indeed, derivative 2a revealed distinct activity in
these cancer cell lines as well. 2a exceeded the activity of 1b
and 1c in KRAS-mutant HCT-116 colon carcinoma cells and
multidrug-resistant KB-V1/Vbl cervix carcinoma cells. The
activity of 2a is particularly high (IC50 = 0.19 lM) in the
Pgp-transporter (P-glycoprotein) overexpressing KB-V1/Vbl
cervix cancer cells. The high efficacy of 2a against these, 1c, and 2a–d in triple-negative MDA-MB-231 breast carcinoma,
ostate carcinoma cells. X-axis: concentrations in lM.
Figure 3 Growth inhibitory activity (MTT assay) of compound
2a against prostate epithelial RWPE-1 cells. X-axis: concentra-
tions in lM.
Table 1 Inhibitory concentrations IC50 (72 h) [lM] of com-
pounds 1b, 1c, and 2a from MTT tests against cells of 518A2
melanoma, vinblastine-resistant KB-V1/Vbl cervix carcinoma,
HCT-116 colon carcinoma, and HT-29 colon carcinoma. Mean
of three values, standard deviation <±15%.
Compd./cell line 1b 1c 2a
518A2 2.58 2.33 2.60
KB-V1/Vbl 0.41 0.93 0.19
HCT-116 6.39 5.02 4.24
HT-29 5.12 2.39 3.58
Ferrocene modified lawsone Mannich bases 109Pgp-positive tumor cells is in line with a recent report of the
natural naphthoquinone and Pgp-substrate plumbagin (iso-
lated from Plumbago species) that was turned into a very active
compound against Pgp-expressing cells after conjugation with
a ferrocene scaffold [28].
4. Conclusions
A series of four new ferrocene-modified lawsone Mannich
bases 2a–d was prepared by a simple one-step three-
component reaction protocol from lawsone 1a and appropri-
ately substituted aryl aldehydes and alkyl amines. Ferrocene
2a was the most active Mannich base of this series. The com-
bination of lawsone with a 2-pyridyl moiety and a ferrocene-1-
yl methylamine scaffold as in 2a seems to be optimal concern-
ing anticancer activity. In addition, compound 2a was more
active than known anticancer active lawsone Mannich bases
1b and 1c against prostate cancer PC-3 (AR-negative) and
KB-V1/Vbl (Pgp-positive) cervix carcinoma cells. In these
hormone- and multidrug-resistant cancer cell lines 2a exhibited
excellent sub-micromolar activity and the effect of the fer-
rocene fragment became particularly visible. The possibilities
for further structural fine-tuning render 2a a promising lead
compound for the development of new drugs for the treatment
of hormone-refractory prostate carcinomas that don’t respondto hormone therapy anymore, as well as for the treatment of
multidrug-resistant tumors with elevated Pgp-levels.Acknowledgement
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